WO2000055321B1 - Vertebrate protein slit, dna sequence encoding it and uses thereof - Google Patents
Vertebrate protein slit, dna sequence encoding it and uses thereofInfo
- Publication number
- WO2000055321B1 WO2000055321B1 PCT/US2000/007040 US0007040W WO0055321B1 WO 2000055321 B1 WO2000055321 B1 WO 2000055321B1 US 0007040 W US0007040 W US 0007040W WO 0055321 B1 WO0055321 B1 WO 0055321B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- cells
- slit
- polynucleotide
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
Abstract
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00916449A EP1163336A2 (en) | 1999-03-17 | 2000-03-16 | Vertebrate protein slit, dna sequence encoding it and uses thereof |
| AU37551/00A AU3755100A (en) | 1999-03-17 | 2000-03-16 | Vertebrate slit dna sequence, protein and uses thereof |
| CA002365214A CA2365214A1 (en) | 1999-03-17 | 2000-03-16 | Vertebrate protein slit, dna sequence encoding it and uses thereof |
| JP2000605739A JP2002538823A (en) | 1999-03-17 | 2000-03-16 | Vertebrate slit DNA sequences, proteins and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12476799P | 1999-03-17 | 1999-03-17 | |
| US60/124,767 | 1999-03-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2000055321A2 WO2000055321A2 (en) | 2000-09-21 |
| WO2000055321A3 WO2000055321A3 (en) | 2001-06-28 |
| WO2000055321B1 true WO2000055321B1 (en) | 2001-07-19 |
Family
ID=22416700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/007040 Ceased WO2000055321A2 (en) | 1999-03-17 | 2000-03-16 | Vertebrate protein slit, dna sequence encoding it and uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1163336A2 (en) |
| JP (1) | JP2002538823A (en) |
| AU (1) | AU3755100A (en) |
| CA (1) | CA2365214A1 (en) |
| WO (1) | WO2000055321A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754982B2 (en) * | 1999-03-18 | 2002-11-28 | Regents Of The University Of California, The | Compositions for promoting nerve regeneration |
| EP2036921A1 (en) * | 2007-09-14 | 2009-03-18 | Scil Technology GmbH | Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| CA2699411A1 (en) * | 2007-09-14 | 2009-03-19 | Scil Technology Gmbh | Neuroendocrine factors for treatment of degenerative diseases |
| WO2014194402A1 (en) | 2013-06-04 | 2014-12-11 | The Hospital For Sick Children | Methods and uses of slit for treating fibrosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992010518A1 (en) * | 1990-12-07 | 1992-06-25 | Yale University | Purified slit protein and sequence elements thereof |
-
2000
- 2000-03-16 EP EP00916449A patent/EP1163336A2/en not_active Withdrawn
- 2000-03-16 JP JP2000605739A patent/JP2002538823A/en active Pending
- 2000-03-16 AU AU37551/00A patent/AU3755100A/en not_active Abandoned
- 2000-03-16 CA CA002365214A patent/CA2365214A1/en not_active Abandoned
- 2000-03-16 WO PCT/US2000/007040 patent/WO2000055321A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2365214A1 (en) | 2000-09-21 |
| WO2000055321A3 (en) | 2001-06-28 |
| JP2002538823A (en) | 2002-11-19 |
| AU3755100A (en) | 2000-10-04 |
| EP1163336A2 (en) | 2001-12-19 |
| WO2000055321A2 (en) | 2000-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100205078B1 (en) | Basic fibroblast growth factor and the method of preparing the same | |
| CA2195799C (en) | Bacterial production of hydrophobic polypeptides | |
| US8557768B1 (en) | Human nerve growth factor by recombinant technology | |
| JP2882775B2 (en) | Human-glia-derived neurite factor | |
| KR100191697B1 (en) | Enzymatic Preparation of Basic Fibroblast Growth Factor | |
| NZ207337A (en) | Human nerve growth factor (hngf), prepared by recombinant technology | |
| CZ287810B6 (en) | DNA sequence, DNA recombinant molecule containing thereof, process for preparing a protein from the TGF-beta substance group, pharmaceutical preparation in which the protein is comprised, antibody or a fragment thereof and use of the antibody | |
| BR9712348A (en) | isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue. | |
| CA2257839A1 (en) | Gamma-heregulin | |
| AU704515C (en) | Novel protein and process for producing the same | |
| KR927002375A (en) | Megakaryocyte forming factor | |
| EP0769020A1 (en) | NEW hIL-4 MUTANT PROTEINS USED AS ANTAGONISTS OR PARTIAL AGONISTS OF HUMAN INTERLEUKIN 4 | |
| WO1989004832A1 (en) | Analogs of fibroblast growth factor | |
| KR950704356A (en) | Progenitor B CELL STIMULATING FACTOR | |
| CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
| EP0476233B1 (en) | Human MK gene and protein sequence | |
| US6511823B1 (en) | Heparin binding neurotrophic factor gene sequence | |
| KR910002520B1 (en) | Cell growth inhibitory factor | |
| Kono et al. | Eclosion hormone of the silkworm Bombyx mori Expression in Escherichia coli and location of disulfide bonds | |
| DE69837507T2 (en) | Human hedgehog protein | |
| WO2000055321B1 (en) | Vertebrate protein slit, dna sequence encoding it and uses thereof | |
| CN1504573A (en) | Confluent protein capable of self-cracking into polypeptide with antibiosis and reparation function | |
| Jung et al. | Biochemical and molecular characterization of an antifungal protein from Tenebrio molitor larvae | |
| CA2223503A1 (en) | Transferrin receptor genes | |
| Chakraborty et al. | Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in streptomyces avermitilis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| B | Later publication of amended claims | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 37551/00 Country of ref document: AU |
|
| ENP | Entry into the national phase in: |
Ref document number: 2365214 Country of ref document: CA Ref country code: CA Ref document number: 2365214 Kind code of ref document: A Format of ref document f/p: F |
|
| ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2000 605739 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000916449 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000916449 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000916449 Country of ref document: EP |